Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications
Teduglutide is associated with significant ADRs necessitating vigilant monitoring while managing SBS patients, particularly for gastrointestinal health and infection risks. FAERS data limitations restrict causality determination, highlighting the need for further research to optimize safety.
Authors
- Praneeth Kudaravalli (ORCID: https://orcid.org/0000-0001-8242-8729)
- Douglas G. Adler (ORCID: https://orcid.org/0000-0003-3214-6285)
- Michael B. Andrews (ORCID: https://orcid.org/0000-0002-2969-4769)
Institutions
- Virginia Commonwealth University (US)
- Porter Adventist Hospital (US)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1080/14740338.2025.2493355
- Citations
- 3
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.14